Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry Kenakin

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Current Opinion in Pharmacology|October 12, 2010
The role of conformational ensembles of seven transmembrane receptors in functional selectivityNagarajan Vaidehi, Terry Kenakin
Nature Reviews. Drug Discovery|May 18, 2013
Measurements of ligand bias and functional affinityTerry Kenakin, Arthur Christopoulos
Nature Reviews. Drug Discovery|February 16, 2013
Signalling bias in new drug discovery: detection, quantification and therapeutic impactTerry Kenakin, Arthur Christopoulos
Trends in Pharmacological Sciences|June 27, 2002
The ligand paradox between affinity and efficacy: can you be there and not make a difference?Terry Kenakin, Ongun Onaran
Biochemical Pharmacology|August 20, 2013
Defining and characterizing drug/compound functionTerry Kenakin, Michael Williams
Pharmacological Reviews|April 16, 2010
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discoveryTerry Kenakin, Laurence J Miller
Trends in Pharmacological Sciences|June 11, 2018
PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?Terry Kenakin, Ryan T Strachan
The Journal of Pharmacology and Experimental Therapeutics|July 22, 2006
Determining the potency and molecular mechanism of action of insurmountable antagonistsTerry Kenakin, Stephen Jenkinson, Christian Watson
Receptors & Channels|April 15, 2003
GPCR drug discovery through the exploitation of allosteric drug binding sitesStephen Rees, Dwight Morrow, Terry Kenakin
Frontiers in Pharmacology|December 24, 2015
Editorial: Orphan GPCRs As Emerging Drug TargetsYe Fang, Terry Kenakin, Changlu Liu
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Current Opinion in Pharmacology|October 12, 2010
The role of conformational ensembles of seven transmembrane receptors in functional selectivityNagarajan Vaidehi, Terry Kenakin
Nature Reviews. Drug Discovery|May 18, 2013
Measurements of ligand bias and functional affinityTerry Kenakin, Arthur Christopoulos
Nature Reviews. Drug Discovery|February 16, 2013
Signalling bias in new drug discovery: detection, quantification and therapeutic impactTerry Kenakin, Arthur Christopoulos
Trends in Pharmacological Sciences|June 27, 2002
The ligand paradox between affinity and efficacy: can you be there and not make a difference?Terry Kenakin, Ongun Onaran
Biochemical Pharmacology|August 20, 2013
Defining and characterizing drug/compound functionTerry Kenakin, Michael Williams
Pharmacological Reviews|April 16, 2010
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discoveryTerry Kenakin, Laurence J Miller
Trends in Pharmacological Sciences|June 11, 2018
PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?Terry Kenakin, Ryan T Strachan
The Journal of Pharmacology and Experimental Therapeutics|July 22, 2006
Determining the potency and molecular mechanism of action of insurmountable antagonistsTerry Kenakin, Stephen Jenkinson, Christian Watson
Receptors & Channels|April 15, 2003
GPCR drug discovery through the exploitation of allosteric drug binding sitesStephen Rees, Dwight Morrow, Terry Kenakin
Frontiers in Pharmacology|December 24, 2015
Editorial: Orphan GPCRs As Emerging Drug TargetsYe Fang, Terry Kenakin, Changlu Liu
Pageof 12